Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is a commercial-stage biotechnology company with a diverse pipeline of potential therapies for oncology, infectious, and autoimmune diseases. With their flagship product, KIMMTRAK, showing strong commercial momentum in the treatment of mUM, the company's valuation is further bolstered by promising late-stage data across its other drug candidates. While there are inherent risks associated with clinical development and commercialization, the company's leadership in the space and proven success in the market make it a strong investment opportunity.

Bears say

Immunocore Holdings is facing challenges as its primary product KIMMTRAK's OS benefit is primarily driven by subsequent therapies, resulting in only 44% of patients being treated with KIMMTRAK alone and 57% of patients discontinuing treatment beyond radiographic progression. Additionally, the company's other drug candidates are still in early stages of development, making it difficult to predict their potential success. The upcoming presentation of five-year OS data at AACR may provide a short-term boost, but the overall outlook for the company remains negative due to these fundamental challenges.

Immunocore Holdings (IMCR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 8 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.